Ultragenyx proposes $138 million Dimension takeover
18 September 2017
USA-based rare diseases specialist Ultragenyx Pharmaceutical has made a proposal to acquire all of the outstanding shares of common stock of Dimension Therapeutics for $5.50 per share, or approximately $138 million, in cash.
Dimension Therapeutics is a US gene therapy company focused on rare diseases.
More on this story...
Today's issue
Company Spotlight
A clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics for the treatment of metabolic diseases, inflammation, and other indications.
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze